2-Chloro-5-Iodobenzoic Acid CAS 19094-56-5 Empagliflozin Intermediate Assay ≥99.0% (HPLC)

Chemical Name: 2-Chloro-5-Iodobenzoic Acid  CAS: 19094-56-5 Assay: ≥99.0% (HPLC) Appearance: White or Pale Yellow Crystals  Intermediate of Empagliflozin (CAS: 864070-44-0) for the treatment of type 2 diabetes High Quality, Commercial Production Inquiry: alvin@ruifuchem.com

Products Details

Chemical Properties:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement. Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture.Manufacturer Supply, High Purity, Commercial Production  Chemical Name: 2-Chloro-5-Iodobenzoic Acid  CAS: 19094-56-5
Item Specifications
Appearance White or Pale Yellow Crystals 
Assay / Analysis Method ≥99.0% (HPLC)
Melting Point 161.0~163.0℃
Loss on Drying ≤0.50%
Residue on Ignition ≤0.20%
Total Impurities ≤1.0%
Heavy Metals ≤20ppm
Residual Solvent Ethanol
Test Standard Enterprise Standard
Usage Intermediate of Empagliflozin (CAS: 864070-44-0)  
2-Chloro-5-Iodobenzoic Acid (CAS 19094-56-5) Synthetic Route cas route 19094-56-5

Description:

Specifications:

Package & Storage:

Chemical Name 2-Chloro-5-Iodobenzoic Acid
CAS Number 19094-56-5
CAT Number RF-PI438
Stock Status In Stock, Production Scale Up to Tons
Molecular Formula C7H4ClIO2
Molecular Weight 282.46
Solubility Soluble in Methanol
Brand Ruifu Chemical

Advantages:

FAQ:

Application:

2-Chloro-5-Iodobenzoic Acid (CAS: 19094-56-5) can be used as a pharmaceutical intermediate in the synthesis of Empagliflozin (CAS: 864070-44-0). Empagliflozin (trade name Jardiance) is an inhibitor of the sodium glucose co-transporter-2 (SGLT-2), and causes sugar in the blood to be excreted by the kidneys and eliminated in urine. On August 1, 2014, the Food and Drug Administration (FDA) officially approved the drug for the treatment of type 2 diabetes, to improve and control blood glucose of adults. Empagliflozin is the third SGLT-2 inhibiting drugs approved by FDA. Another two SGLT-2 inhibitor drugs, Canagliflozin and Dapagliflozin, belonging to Johnson Pharmaceuticals, AstraZeneca and Bristol-Myers Squibb respectively, are approved by FDA in November 2013 and January 2014 respectively.

Contact us

Please feel free to give your inquiry in the form below We will reply you in 24 hours